MRIdian
Device
VIEWRAY TECHNOLOGIES INC
Total Payments
$3.3M
Transactions
524
Doctors
137
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $1.6M | 252 | 85 |
| 2020 | $1.0M | 84 | 13 |
| 2019 | $611,822 | 188 | 63 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 122 | 76.9% |
| Consulting Fee | $400,593 | 37 | 12.3% |
| Royalty or License | $130,321 | 2 | 4.0% |
| Honoraria | $76,008 | 53 | 2.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $46,275 | 37 | 1.4% |
| Space rental or facility fees (teaching hospital only) | $41,000 | 12 | 1.3% |
| Travel and Lodging | $22,824 | 67 | 0.7% |
| Food and Beverage | $18,943 | 191 | 0.6% |
| Charitable Contribution | $10,000 | 1 | 0.3% |
| Education | $5,800 | 2 | 0.2% |
Payments by Type
Research
$2.5M
122 transactions
General
$751,764
402 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Prospective Phase II Study of Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART) for Patients with Borderline or Inoperable Locally Advanced Pancreatic Cancer. | VIEWRAY TECHNOLOGIES INC | $971,736 | 3 |
| SMART Study - Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer | VIEWRAY TECHNOLOGIES INC | $318,103 | 0 |
| Stereotactic MR-guided Adaptive Radiation Therapy (SMART) for Cervical Cancer and Stereotactic MR guided Adaptive Radiotherapy (SMART) in Adjuvant Management of the Post-Operative Female Pelvis | VIEWRAY TECHNOLOGIES INC | $200,000 | 0 |
| A Feasibility Study of Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction for Inoperable Primary or Metastatic Carcinoma (SMART ONE) | VIEWRAY TECHNOLOGIES INC | $105,000 | 0 |
| CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study | VIEWRAY TECHNOLOGIES INC | $75,000 | 0 |
| Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer in 4 Weeks v. 2 Weeks (SHORTER) | VIEWRAY TECHNOLOGIES INC | $63,735 | 0 |
| Deep learning application in real-time automatic tumor detection andtracking for MR-guided adaptive prostate SBRT | VIEWRAY TECHNOLOGIES INC | $61,303 | 0 |
| MR/Radiotherapy researh fellowship | VIEWRAY TECHNOLOGIES INC | $60,000 | 0 |
| Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma | VIEWRAY TECHNOLOGIES INC | $58,743 | 0 |
| Deep Learning Applications for the ViewRay MR-LINAC | VIEWRAY TECHNOLOGIES INC | $53,426 | 0 |
| Towards anatomically and functionally guided adaptive radiotherpy ofcervical tumors | VIEWRAY TECHNOLOGIES INC | $53,426 | 0 |
| Low field perfusion and diffusion imaging via selfsupervised deeptransform learning | VIEWRAY TECHNOLOGIES INC | $53,425 | 0 |
| This study seeks to improve an area of clinical need, RT boost in poorly defined cavities, with a technical innovation, MRgRT on the MRIdian. | VIEWRAY TECHNOLOGIES INC | $50,807 | 0 |
| Evaluation of efficiency gains and the patient experience utilizing an in-bore visual feedback system for management of MR-guided adaptive radiotherapy | VIEWRAY TECHNOLOGIES INC | $49,600 | 0 |
| SMARTer: Development of an Eductional Resource to Faciliate Online Adaptive Radiotherapy | VIEWRAY TECHNOLOGIES INC | $42,651 | 0 |
| High-Precision Cardiac Motion Modeling and Gating Using the MRIdian System - Healthy Volunteer Study | VIEWRAY TECHNOLOGIES INC | $31,184 | 0 |
| Nanobody Immune-guided Radiation Therapy | VIEWRAY TECHNOLOGIES INC | $30,000 | 0 |
| Feasibility and efficacy of neoadjuvant MR-guided radiotherapy with concurrent carboplatin/paclitaxel in locally advanced gastric cancer) | VIEWRAY TECHNOLOGIES INC | $29,063 | 0 |
| MRI Guided Cavity Radiation in Resected Brain Metastasis | VIEWRAY TECHNOLOGIES INC | $28,839 | 0 |
| Evaluation of video sign out to improve the efficiency and safety of MRI guided online adaptive radiation therapy | VIEWRAY TECHNOLOGIES INC | $25,750 | 0 |
Top Doctors Receiving Payments for MRIdian
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Detroit, MI | $3.1M | 155 |
| , MD | Radiation Oncology | Miami, FL | $59,132 | 61 |
| , M.D | Radiation Oncology | Los Angeles, CA | $24,314 | 20 |
| , M.D | Radiation Oncology | New York, NY | $14,408 | 12 |
| , MD | Radiation Oncology | Saint Louis, MO | $12,538 | 6 |
| , M.D | Radiation Oncology | Boston, MA | $10,452 | 9 |
| , MD | Radiation Oncology | Los Angeles, CA | $8,050 | 5 |
| , M.D | Radiation Oncology | Los Angeles, CA | $6,300 | 7 |
| , M.D | Radiation Oncology | Los Angeles, CA | $5,950 | 5 |
| , M.D | Radiation Oncology | Miami, FL | $3,636 | 4 |
| , MD | Hematology & Oncology | Miami, FL | $3,400 | 1 |
| , MD | Radiation Oncology | Detroit, MI | $3,200 | 2 |
| , MD | Radiation Oncology | Saint Louis, MO | $3,000 | 2 |
| , M.D | Radiation Oncology | Fort Wayne, IN | $2,428 | 20 |
| , MD | Radiation Oncology | Miami, FL | $1,659 | 3 |
| , M.D | Radiation Oncology | Miami, FL | $1,600 | 1 |
| , MD | Radiation Oncology | Saint Louis, MO | $1,371 | 1 |
| , MD, PH.D | Diagnostic Radiology | Phoenix, AZ | $1,362 | 6 |
| , MD | Radiation Oncology | Saint Louis, MO | $1,310 | 2 |
| , M.D | Radiation Oncology | Chicago, IL | $1,273 | 10 |
| , MD, PHD | Radiation Oncology | Portland, OR | $1,222 | 8 |
| , M.D | Radiation Oncology | Orlando, FL | $1,200 | 1 |
| , MD | Radiation Oncology | Honolulu, HI | $1,078 | 2 |
| , MD | Radiation Oncology | Saint Louis, MO | $1,069 | 3 |
| , MD | Diagnostic Radiology | Hillsboro, OR | $1,000 | 1 |
Ad
Manufacturing Companies
- VIEWRAY TECHNOLOGIES INC $3.3M
Product Information
- Type Device
- Total Payments $3.3M
- Total Doctors 137
- Transactions 524
About MRIdian
MRIdian is a device associated with $3.3M in payments to 137 healthcare providers, recorded across 524 transactions in the CMS Open Payments database. The primary manufacturer is VIEWRAY TECHNOLOGIES INC.
Payment data is available from 2019 to 2021. In 2021, $1.6M was paid across 252 transactions to 85 doctors.
The most common payment nature for MRIdian is "Unspecified" ($2.5M, 76.9% of total).
MRIdian is associated with 20 research studies, including "Prospective Phase II Study of Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART) for Patients with Borderline or Inoperable Locally Advanced Pancreatic Cancer." ($971,736).